Cytokine-associated pathogenic profile as a guide for targeted therapy in pityriasis rubra pilaris

Affiliations

¹ Department of Dermatology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong Province, China.
² Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.

Liu-Yu Chen et al. J Eur Acad Dermatol Venereol. 2025.

. 2025 Nov 24.

doi: 10.1111/jdv.70221. Online ahead of print.

¹ Department of Dermatology, The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen, Guangdong Province, China.
² Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.

No abstract available

Keywords: guselkumab; immune profile; pityriasis rubra pilaris; targeted therapy; ustekinumab.

References

1. Ji‐Xu A, Lei DK, Worswick S, Maloney NJ, Kim MM, Cutler L. Patient and disease characteristics associated with psychiatric symptoms and impaired quality of life in pityriasis rubra pilaris. Br J Dermatol. 2022;187(6):1024–1026.
1. Engelmann C, Elsner P, Miguel D. Treatment of pityriasis rubra pilaris type I: a systematic review. Eur J Dermatol. 2019;29(5):524–537.
1. Maloney NJ, Hisaw LD, Worswick S. Refractory pityriasis rubra pilaris treated with etanercept, adalimumab, or ustekinumab: a retrospective investigation. Dermatol Ther. 2017;30(6):e12559. https://doi.org/10.1111/dth.12559
1. Tran TS, Nguyen TM, Lehman JS, Wetter DA, Nguyen GH. Treatment of pityriasis rubra pilaris with systemic and biological agents: a single‐center retrospective cohort of 76 patients. J Am Acad Dermatol. 2025;92(6):1362–1365.
1. Boudreaux BW, Pincelli TP, Bhullar PK, Patel MH, Brumfiel CM, Li X, et al. Secukinumab for the treatment of adult‐onset pityriasis rubra pilaris: a single‐arm clinical trial with transcriptomic analysis. Br J Dermatol. 2022;187(5):650–658.